TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines Ltd., a Swiss-incorporated company, announced its unaudited financial results for the third quarter and nine months ending September 30, 2025. The company has provided business updates and revised its financial guidance for the full year. The results, prepared under U.S. GAAP, highlight key business milestones and expectations for continued global expansion and investment. The announcement also includes insights into BeOne’s strategic focus on achieving regulatory milestones and enhancing its market position with its drug candidates.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 5,386,090
Technical Sentiment Signal: Buy
Current Market Cap: HK$275.5B
For a thorough assessment of 6160 stock, go to TipRanks’ Stock Analysis page.